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Human endogenous retroviruses (HERVs) are remnants from ancient retroviral
infections, and most of them are inactive in normal tissues. One family of HERV,
HERV-K, is found to be associated with multiple human cancers including breast
cancer, pancreatic cancer and melanoma, but the causal relationship between HERV-K
and cancer is still unclear. Increased expression of HERV-K in melanoma cells
correlates with malignant transformation, while a serological response to HERV-K in
breast cancer or melanoma patients correlates with survival probability. However, the
mechanism behind these observations remains obscure. Our laboratory reported that
anti-HERV-K envelope (Env) protein antibodies show antitumor potential in targeting
breast tumors, indicating that HERV-K Env (Kenv) may play an important role in
tumorigenesis. In this study, we used either knockdown (main focus) or over-expression
approach, to investigate the role of Kenv in breast cancer, pancreatic cancer, and
melanoma. Compared to the control cells, all the cancer cell lines transduced with Kenvspecific shRNA (shRNAenv) exhibited lower proliferation rates and lower tumorigenic
potential in vitro, and some showed lower migration/ invasion rate. In vivo, tumorigenic
potential of all the shRNAenv transduced cell lines was found to be reduced after
inoculation into nude mice or NOD/SCID gamma (NSG) mice. Moreover, results from
RNA Seq and Ingenuity Pathway Analysis (IPA) suggested the involvement of Kenv in
v

the mevalonate pathway. In addition, introduction of Kenv into the premalignant human
breast cell line MCF-10AT led to increased cell proliferation and colony formation.
These results suggest that Kenv plays specific and important roles in progression of
human breast cancer, pancreatic cancer, and melanoma.
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Chapter 1 Introduction
In 1908, Oluf Bang and Vilhelm Ellerman studied leukemia in chickens and found
that the disease could be transmitted to new chickens by cell-free tissue filtrates. In 19101911, Peyton Rous confirmed similar results for solid tumors in chickens and
subsequently isolated the infectious agent, a virus later named as Rous sarcoma virus
(RSV) (1). Based on these findings, a theory that viruses can cause cancer was proposed.
Since then, more and more evidence has been accrued to support this theory: in 1933,
Richard Edwin Shope discovered the first mammalian tumor virus, Shope
papillomavirus, in rabbit (2); in 1964, Anthony Epstein, Bert Achong and Yvonne Barr
discovered the first human cancer virus, Epstein-Barr Virus (EBV), from Burkitt
lymphoma cells (3); in 1970, G. Steven Martin discovered the first confirmed oncogene,
v-src (which was termed a few years later), from a mutant RSV strain (4). Until the
present, 6 viruses acknowledged to cause human cancer have been discovered: EBV
(Burkitt’s lymphoma, Hodgkin’s lymphoma, nasopharangeal carcinoma), hepatitis B
virus (HBV) and hepatitis C virus (HCV) (hepatocellular carcinoma), human Tlymphotropic virus 1 (HTLV-1) (adult T-cell leukemia and lymphoma), high risk human
papillomavirus (HPV) (cervical cancer), and Kaposi’s sarcoma-associated herpesvirus
(KSHV or HHV8) ( Kaposi’s sarcoma) (5-8).
Despite only 6 human cancer viruses having been widely acknowledged, more
viruses have been proven to be at least associated with human cancers, such as Merkel
cell polyomavirus (MCPyV) (Merkel cell carcinoma), cytomegalovirus (CMV) (brain
tumor) (6), and human endogenous retrovirus-K (HERV-K) (seminoma, breast cancer,
1

prostate cancer, ovarian cancer, melanoma) (9). This section will focus on general
features of HERV-K and its association with multiple human cancers.
1.1 Human endogenous retrovirus (HERV)
1.1.1

HERV features

Retroviruses are RNA viruses defined by their expression of reverse transcriptase
(RT). During the replication cycle of retroviruses (Figure 1), there are two critical steps
which are intermediated by two virally coded enzymes: reverse transcription, the
conversion of viral genomic RNA into DNA, mediated by RT; and the integration of
newly-synthesized viral DNA into the host genome that follows reverse transcription,
mediated by integrase (10). Virion particles are spherical with a diameter of
approximately 80-100 nm. Virus particles contain 2 copies of sense RNA of ~8 to 10 kb
in length, which together with nucleocapsid protein form the viral ribonucleoprotein
complex. The nucleocapsid is surrounded by a spherical layer of protein, called the
capsid protein, and the outer layer is the viral envelope, which is a lipid bilayer
membrane distributed with envelope glycoprotein. The schematic structure of a retroviral
particle is shown in Figure 2 (11).
Usually retroviruses do not lyse the host cells, and thus integration allows a longterm association between the virus and the host cell. When a germ cell is infected by a
retrovirus, colonization of the germ line by the virus is possible. Such inherited
proviruses are called endogenous retroviruses (ERVs), and they provide evidence of
ancient retroviral infections dating back many millions of years (10).
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Figure 2. Schematic structure of a retroviral particle. Reprinted from reference (11)
under the open access policy of BioMed Central.
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Human endogenous retroviruses (HERVs) were first discovered in the 1980s (12).
They are believed to have become integrated into the human genome around 35 million
years ago via infection of the germline, which is supported by the fact that most HERVs
appear to be ancient and are found in both Old and New World monkeys (this suggests
that the first integration happened before the divergence of New World and Old World
monkeys), and have been sustained there as vertically transmitted proviruses since that
time (13, 14).
HERVs represent about 8% of the human genome and are widely dispersed (15).
However, the majority of HERVs are incomplete, and in most cases HERVs are inactive.
As most retroviral infections could be harmful to the host cells, evolutionary selection
ensures that HERVs are disabled by mutations that prevent expression of some or all
proviral genes during evolution. In most cases, almost the entire proviral genome was
excised as a result of recombination of the two long terminal repeats (LTRs), and only a
single (solitary) LTR was left. Even if the viral genome persists, other mutations, such as
smaller deletions, frame shifts and premature stop codons, could prevent the expression
of functional proteins from most HERV loci (16). In addition, epigenetic mechanisms
including hypermethylation and histone modifications provide a further mechanism for
silencing HERV provirus expression (16-18).
The genome of HERVs is composed of gag, pro, pol, and env genes. The gag gene
codes for the structural matrix (MA), capsid (CA), and nucleocapsid (NC) proteins, the
pro gene codes for protease (PR) protein, the pol gene codes for the enzymes of RT and
integrase (IN), and the env gene codes for the envelope surface (SU) and transmembrane
(TM) proteins. The retroviral genome is flanked by two LTRs that regulate viral gene
5

transcription. Each LTR contains unique 3’ (U3), repeat (R) and unique 5’ (U5)
elements. The genomic structure of HERVs is illustrated in Figure 3. (19)
According to the mechanism of reverse transcription, the two LTRs should be
identical. However, with time, they could undergo divergence due to various mutations
acquired during cellular DNA replication, so the divergence between the two LTRs could
be used as a molecular clock to understand the evolutionary radiation of the HERV
family. In addition, multiple copy numbers of solitary LTR elements of the HERV-K
family have been identified as being unique to humans. Therefore, solitary LTR elements
could provide valuable information regarding the evolutionary history of retroelements
within the primate genome (19). This information indicates that analysis of HERV LTRs
can be used to determine the timeframe of HERV integration.
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1.1.2 HERV classification and nomenclature
Based on the degree of pol sequence homology, retroviruses can be divided into
several groups. HERVs belong to the beta-, gamma-, or spuma- retrovirus groups. No
sequences with homology to delta- or lenti- viruses have been found in the human
genome, although endogenous lentivirus genomes were discovered in basal primates,
such as owl monkeys and macaques (10, 20). However, HTLVs, members of deltaretrovirus group, do share some common characteristics with certain HERVs, and these
HERVs also exhibit splicing patterns comparable to the splicing in the more complex
exogenous retroviruses (21). A phylogenetic tree has been created for human endogenous
retroviruses as shown in Figure 4.
In general, gamma-retroviruses represent most HERV families. They have the largest
genomic fraction (22) and are murine leukemia virus (MLV)-like (21). Beta-retroviruses
contain the HERV-K elements and older retroviral families (23), and are murine
mammary tumor virus (MMTV)-like (also often named human MMTV-like viruses,
HML)(21). Spuma-retroviruses contain the oldest recognizable HERV elements (15).
HERVs can be further classified and named using the single letter amino acid code
for the tRNA specificity of the primer binding site used to initiate reverse transcription.
Thus, HERV-W would use a tryptophan tRNA if it were an infectious virus, and HERVK would use lysine (16). To date, 31 HERV families have been identified and are named
according to the tRNA used to prime reverse transcription. However, based on sequence
homology, HERVs can be grouped into 80 distinct families (24). An overview of
representative HERV families is presented in Table 1.
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The conventional HERV classification and naming scheme may cause some
problems, as it becomes inadequate when two HERVs are found to use the same tRNA
(25). In addition, in some cases, the primer binding site sequence was not available when
novel elements were first discovered, and thus they were named based on neighboring
genes (e.g., HERV-ADP), clone number (e.g., HERV-S71) or amino acid motifs (e.g.,
HERV-FRD). Additional designations based on the probe used for cloning (e.g., HERVHML) and sub-divisions based on the degree of sequence identity in RT or phylogenetic
reconstructions (e.g., HERV-K(HML-2)) have also been used. More recently,
phylogenetic methods have been used to define different groups of HERV sequences
(10).
The copy number of a specific type of HERVs in human genome varies greatly, from
a single copy (eg, HRES-1), to 1000 copies (eg, HERV-H). The distribution of HERV
sequences is found most concentrated in chromosomes Y, X, 4 and 20 (12).
1.1.3 Normal physiological effects of HERV
Among all the ERV members, only a few elements may still be infectious in some
host species, and the reason may be that they have been recently integrated into the
genome of their host and they are still able to replicate and integrate new proviral copies
within the germline. Koala endogenous retrovirus is an unique example, because it is not
only threatening the species with extinction, but also it is an example of an infectious
retrovirus that is currently undergoing endogenization (21). Other examples of these
infectious ERVs are endogenous jaagsiekte sheep retrovirus (enJSRV), causing lung
cancer in sheep; feline leukemia virus, causing leukemia and lymphomas in cats; MLV,
causing leukemia in mice; and MMTV, causing breast cancer in mice (16, 21). However,
11

in humans, infectious HERVs have not been found yet (10, 16, 21), although a single
cycle infectivity has been demonstrated by ‘HERV-KCON’, a reconstituted clone of
human-specific HERV-K(HML-2), the youngest and the most active group of HERV-K
elements (26).
As the majority HERVs are inactive in normal conditions, it was widely held that
HERVs were ‘junk’ DNA ‘fossils’ of ancestral infections by exogenous retroviruses (14,
16, 24). However, the fact that HERVs represent such a large portion of the human
genome makes it less compelling that HERVs are really all ‘junk’. Conservation of
HERVs in the human genome through evolution implies a positive evolutionary selection
exerted by the host because HERVs may have introduced some beneficial effects to the
host (14, 27). Several such effects have been proposed, as shown below.
First, HERVs may play a major role in shaping our genome by increasing its
plasticity, and in the evolution of gene regulation networks. Some sequences of HERVs
are targets for genomic rearrangements, and thus could contribute to the shaping and
plasticity of the genome (28). LTR elements of HERVs contain numerous regulatory
sequences, including effective promoters, enhancers, polyadenylation signals, and
transcription factor binding sites, and these LTRs could also modulate transcriptional
regulation, which contributed to primate evolution (14, 19). Examples of the roles played
by HERVs in changing the genetic landscape include: the LTR of HERV-E is used as an
alternative promoter for the endothelin B receptor and apolipoprotein C-I genes in
humans; the HERV-K LTR promotes alternative splicing and encodes the 67 carboxyterminal amino acid residues in human leptin receptor protein; insertion of the HERV-H
LTR provides the polyadenylation signals to human HHLA2 and HHLA3 genes; and
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consensus sequences of HERV LTRs contain multiple binding sites for transcription
factors such as p53, CTCF, Pou5F1-Sox2, and ESR1 (19).
Second, some HERV envelope (Env) proteins likely play important roles in placenta
formation. High expression levels of HERV-W and HERV-FRD Env proteins, named
syncytin-1 and syncytin-2, respectively, as well as other retrovirus Env proteins, are
detected in syncytiotrophoblasts, but not in cytotrophoblasts. These retrovirus Env
proteins are anchored in the lipid bilayer of cell surface membranes, and exhibit cell-cell
fusogenic activity. So these HERV Env proteins probably contribute to the physiological
placenta morphogenesis by mediating fusion of cytotrophoblasts to syncytiotrophoblasts.
In addition, the known immunosuppressive property of syncytin-2 and other HERV Env
proteins (although not syncytin-1), suggests that these HERV Env proteins may
contribute to prevent allogeneic rejection of the fetus at the fetal multinucleated villous
syncytiotrophoblast layer, and HERVs may therefore be instrumental in safeguarding
placental morphogenesis, physiology and fetal–maternal tolerance (14).
Third, HERVs can protect the host against exogenous virus infection, which is
potentially oncogenic or immunosuppressive via interference with their receptors or the
formation of antisense mRNA; this inhibitory interference is a general feature in animal
retrovirology. For example, HERV-W Env glycoproteins can confer cellular resistance to
superinfection by exogenous retroviruses as shown in vitro (12, 14).
Finally, HERV-encoded proteins may help the host fight against cancer. HERV-E is
activated in a proportion of renal cancer cells, and was shown to provide target antigens
recognizable by cytotoxic T-cells from donors after allogeneic hematopoetic stem cell
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transplantation, which led to complete (10%) or partial (30%) tumor regression in
patients (14). Another example is HERV-K Env (Kenv) protein, which could trigger both
serologic and cellular immune responses, leading to the killing of HERV-K expressing
cancer cells (29, 30).
1.1.4 HERVs and human disease
Considering the disease-inducing properties of exogenous human retroviruses, it’s
not surprising that HERVs also have detrimental effects (14). As discussed above, the
majority of HERVs are silent under normal conditions, however, they become
transcriptionally and even translationally active under altered physiological conditions,
and show close association with some human diseases. These diseases include: male
infertility (10, 19); autoimmune diseases such as rheumatoid arthritis, psoriasis, systemic
lupus erythematosis, and Sjögren’s syndrome (21); neuropathogenic diseases such as
multiple sclerosis and schizophrenia(21); and in particular, multiple cancers such as
breast cancer and melanoma.
The association between HERVs and human cancer has been proposed for decades
(14). An increased expression of HERVs in different tumors has been reported by many
groups (Table 2), and this upregulation is not biased to any particular type of cancer. The
trend of cancer-specific upregulation seems to be true across a broad spectrum of HERV
families (9).
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As mentioned earlier, while infectious and potentially oncogenic ERVs exist in some
animal species, no evidence shows the existence of an infectious, horizontally
transmissible HERV, although the possibility can not be excluded (14). Without this
direct evidence, although the association between HERVs and human cancer has been
widely acknowledged, the causal relationship between the two is still a mystery: it is still
unknown whether activation of HERVs initiates/ promotes cancer development or is a
result of altered gene regulation in cancer cells. However, there is accumulating evidence
for HERV involvement in the process of carcinogenesis, and several potential
mechanisms of the role of HERV in this process have been proposed (9, 14, 28, 31).
First, HERV retrotransposition, HERV-mediated recombination, and epigenetic
regulation of HERV LTRs have the potential to enhance oncogene expression or inhibit
the expression of tumor suppressor genes, leading to the transformation of host cells.
Furthermore, recombination between the thousands of HERV loci may lead to gain-offunction sequences of HERVs, and thus to the generation of an infectious retrovirus.
Second, some HERV-coding proteins may play the role of oncoprotein. Two small
accessory HERV-K proteins, Rec and Np9, which are products of alternative splicing of
the env gene, have demonstrated oncogenic properties and shown direct involvement of
HERV proteins in malignancy.
HERV may also indirectly facilitate cancer development by the immunosuppressive
function of its Env proteins. This immunosuppression may be beneficial in
syncytiotrophoblasts at the fetal-maternal interface (the syncytin case), while it may be
detrimental to the immune surveillance of tumors.
16

1.2 HERV-K function in multiple human cancers
1.2.1

The HERV-K family

HERV-K was first discovered in the late 1970s as ‘‘Human TeratocarcinomaDerived Retroviruses’’ (HTDV), though its HERV attribution was not recognized at that
time (14). In 1986, HERV-K10 was cloned and sequenced because of its sequence
similarity with MMTV (this is where HML-2 (human MMTV-like 2), another name of
HERV-K, arose from), and it was the first time that the whole genome sequence of a
HERV-K provirus became known (16, 32).
Members of the HERV-K family are the youngest among all HERVs, and they
integrated into the human genome between three and six million years ago (31). In
particular, the youngest HERV-K, HERV-K113, which is located on chromosome 19,
has been estimated to have entered the human genome since 200,000 to 2 million years
ago (14, 33). It is estimated that there are about 1,000 copies of HERV-K including
truncated forms and over 2,500 copies of solitary LTRs in the human genome, and more
than 60 copies of HERV-K proviruses per haploid human genome have been further
estimated (14, 19, 34).
Likely because of its later integration, HERV-K is the most complete and
biologically active family, and contains retroelements showing polymorphic integration
in the human genome (10, 16, 19, 31). Several HERV-K proviruses preserve functional
full-length open reading frames (ORFs) coding for all structural, regulatory and
enzymatic viral proteins, and HERV-K is the only known HERV family with this feature
(14, 31). Moreover, it was stated that “HERV-K113 is an excellent candidate for an
endogenous retrovirus that is capable of reinfecting humans today”(35), and this in turn
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suggests that an infectious HERV-K would be the most likely candidate for the discovery
of oncogenic retrovirus (14).
There are two forms of HERV-K: type I and type II HERV-K proviruses, as
described in Figure 5. HERV-K10 belongs to the type 1 proviruses, containing a genome
of ~9.2 kb, and HERV-K113 belongs to type II proviruses, contained an additional 292bp sequence at the boundary of the pol and env genes (16, 32). So the length of HERV-K
genome ranges from ~9.2 kb to ~9.5 kb. The type II HERV-K is considered as the
prototype, and it could express the accessory protein Rec (36). In type I HERV-K, the
292 bp deletion at the pol-env boundary leads to the fusion of the pol and env genes, the
absence of the Rec, and instead the presence of another accessory protein Np9. However,
members of both types could contain all the ORFs required for retroviral replication (16).
Abundant studies have been reported on the relationship between HERV-K and
human diseases, such as rheumatoid arthritis and psoriasis (16, 24). However, the hotspot
of these studies is the association between HERV-K and cancer. HERV-K is thought to
be transcriptionally silent in normal cells, and become active after malignant
transformation (14, 31), except in the case of brain tumor (37). High expression of
HERV-K has been detected in different human cancers, which seems to be tumorspecific (absent or of low expression in normal or adjacent uninvolved tissues) (9, 31).
As described earlier, a causal relationship between HERV-K and cancer is still unknown,
but it has been thought that activation of HERV-K may initiate or maintain
carcinogenesis (31).
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In particular, HERV-K can express two accessory viral proteins, Rec and Np9, which
are not found in other HERVs, and the two proteins are believed to have oncogenic
potential (14). Rec, originally named as cORF, is a functional homologue of the HTLV1
Rex and HIV Rev, and is responsible for the nuclear export of un-spliced or singlespliced viral mRNA into the cytoplasm (14, 38). Rec was capable of transforming Rat-1
(a non-tumorigenic rat fibroblast cell line) cells in vivo in nude mice (39), of contributing
to germ cell tumor development in transgenic mice (40), and of promoting Raji (a human
Burkitt's lymphoma cell line) xenograft tumor growth in NOD-SCID mice (41). Np9 is
exclusively expressed in leukemia, breast cancer and germ cell tumors, but not in normal
cells or cell lines (9, 14). Np9 is thought to act as oncoprotein in germ cell tumors (14,
16), and recently it has been identified as a potent viral oncogene in human leukemia
(41). Both Rec and Np9 could bind to the promyelocytic leukemia zinc finger protein
(PLZF), which is known as a tumor suppressor, a transcriptional suppressor of the c-myc
proto-oncogene, and a spermatogonial stem cell regulator. Co-expression of Rec and
Np9 abolished transcriptional repression of the c-myc gene through binding to PLZF,
leading to increased synthesis of c-Myc protein and proteins regulated downstream of cMyc such as p53, PCNA and IkBa (14, 39, 42). Furthermore, Np9 can bind to and
directly interfere with ligand of numb protein X, a RING-Type E3 ubiquitin ligase, and
thus interfere with the Numb/Notch pathway (43), which is essential for proliferative Ras
signaling, and whose abnormal regulation is suggested to initiate germ cell tumor
development by causing genetic instability (44). These observations collectively provide
molecular mechanisms for the oncogenic potential of the two proteins.
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In addition, HERV-K virus-like particles have been detected in teratocarcinoma (16),
breast cancer (45-47), melanoma (48), and lymphoma (47). However, an attempt to
identify infectious HERV-K viral particles from melanoma was unsuccessful (49), and
indeed no infectious HERV-K proviruses have been discovered to date (14, 16). Two
HERK-K provirus prototype constructs, Phoenix (50) and HERV-KCON (26), have been
independently reconstituted by deriving a consensus sequence of HERV-K. The two
constructs can generate viral particles infectious to both human and animal cells in vitro,
and provide new tools for further study of the oncogenic effects of HERV-K in cancer
(16). HERV-K virus-like particles have also been found in the blood of HIV-1-fnfected
individuals (51).
1.2.2

HERV-K and human breast cancer

Breast cancer is one of the most common cancer types and the second leading cause
of cancer death among women in the US (31). It is estimated that 232,340 new cases of
invasive breast cancer and 64,640 new cases of in situ breast cancer are expected to
occur among women during 2013 (an estimated 2,240 new cases of breast cancer are
expected to be diagnosed in men), with an estimation of 40,030 breast cancer deaths
(39,620 women, 410 men) (52). So breast cancer represents one of the most serious and
costly public health issues in the US (53).
Risk factors for breast cancer include being a woman, increasing age, weight gain
after age 18, obesity, use of menopausal hormone therapy, physical inactivity and
alcohol consumption. Risk is also increased by a strong family history of breast cancer.
Inherited mutations in breast cancer susceptibility genes account for about 5-10% of all
female breast cancers and an estimated 4-40% of all male breast cancers, while they are
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very rare in the general population (much less than 1%). Most of these mutations are
located in BRCA1 and BRCA2 genes (54).
Human breast cancer is a highly heterogeneous cancer type of about 20
morphologically distinct subtypes with substantially different molecular and/or
biochemical signatures, clinical courses, and prognoses (55). This high heterogeneity
suggests different etiologies of breast cancer, such as inherited mutations and
environmental factors, and many studies have been providing substantial, but not
conclusive, evidence that breast cancer might be caused by EBV, MMTV, HPV (56-58)
and HERV-K (31).
The association between breast cancer and HERV-K was first revealed by Ono et al.
in 1987 (59), though the possibility of this association had been suggested by the same
group in 1986 (32). They reported for the first time in the 1987 study that HERV-K
genome expression could be stimulated by hormone treatment in vitro in the human
breast cancer cell line T47D. In 1992, T47D was found to secrete retrovirus-like particles
related to MMTV and with human endogenous origin in a steroid-dependent manner
(60), and three years later, the sequence of HERV-K was identified from these virus-like
particles (45). In 1998, the proviral structure and chromosomal location of the HERV-K
from T47D particles was confirmed (61).
An endogenous DNA sequence with partial homology to MMTV was found in
human breast tumors by Szakacs et al. in 1991 (62), but the identity of the DNA
sequence was not confirmed. However, not until 6 years later were HERV-K transcripts
(env) identified in malignant tissues and in peripheral blood of human breast cancer

22

patients for the first time, along with several other cancers, via RT-polymerase chain
reaction (RT-PCR) by Willer et al. (63).
In 2001, our group reported that type I Kenv transcripts from multiple loci are
frequently expressed in human breast cancer, but not in normal or uninvolved breast
epithelial cells, and that some clones of these transcripts contained no premature
termination codons and were capable of expressing Kenv protein (64). Two years later,
our group also observed the expression of type II Kenv transcripts in human breast
cancer, with a significantly higher level than in normal breast tissues; we also
investigated the splicing patterns of both types of HERV-K, and found that both types
expressed spliced subgenomic env transcripts, which are also tumor-specific. In all, these
studies suggest that multiple HERV-K endogenous retroviral element splice variants
could be novel breast tumor markers (65).
In 2008, Maya Golan et al demonstrated the existence of active HERV-K RT in
human breast cancer, and found its significant correlation with poor prognosis for
disease-free patients and their overall survival, suggesting that HERV-K RT might be
expressed in early malignancy and might serve as a novel prognostic marker for breast
cancer (66). Similar findings regarding Kenv protein have been reported by our group in
2011. We found that the expression of Kenv protein in breast cancer patients is
associated with markers of disease progression and poor disease outcome, thus
suggesting that HERV-K expression may enhance metastasis, and that Kenv protein is a
novel candidate prognostic marker for breast cancer (67). HERV-K elements have also
been discovered in the plasma of people with breast cancer (47).
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To assess the potential of HERV-K as a biomarker for immunotherapy of breast
cancer, we investigated the expression of Kenv protein in human breast cancer, and
reported in 2008 that Kenv protein is expressed in 88% of breast cancer tissues but not in
normal breast tissues, and that it can trigger both humoral and cellular immune
responses. We also produced HERV-K-specific cytotoxic T lymphocytes (CTLs), which
were capable of lysing target cells expressing Kenv protein in breast cancer patients but
not in normal female controls without cancer. These findings suggest that Kenv proteins
are capable of acting as tumor-associated antigens, activating both T-cell and B-cell
responses in breast cancer patients (29). Furthermore, in 2012 we reported that
monoclonal antibodies (mAb) specific to Kenv protein could inhibit growth and induce
apoptosis of breast cancer cells in vitro, and significantly inhibit breast tumor growth in
vivo in a mouse xenograft model, suggesting that mAbs against Kenv protein have
potential as novel immunotherapeutic agents for breast cancer therapy (30).
1.2.3

HERV-K and melanoma

Melanoma is the most serious form of skin cancer. For melanoma patients, when
distant metastases occur the prognosis is very poor, with median survival of less than 1
year and less than 10% of patients alive at 5 years (68). It accounts for the majority of
skin cancer deaths, although accounting for less than 5% of all skin cancer cases. In
2013, an estimated 76,690 new cases of melanoma will be diagnosed in the US and about
12,650 patients will die from the disease. Major risk factors for melanoma include a
personal or family history of melanoma and the presence of atypical or numerous (more
than 50) moles. Other risk factors include sun sensitivity and a history of excessive sun
exposure (54).
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The first evidence showing the association between HERV-K and melanoma was
reported by Schiavetti et al. in 2002. In their study, a human endogenous retroviral
sequence termed HERV-K-MEL, which shows homologies with HERV-K and can
encode an antigen recognized on melanoma by CTLs, was discovered, and was
considered for use in vaccination (69).
As early as 1974, particles resembling retroviruses, which were called RNA tumor
viruses at that time, were found in human melanoma (70). However, not until 2003 were
retrovirus-like particles with sequences homologous to HERV-K discovered by Muster
et al. in human melanoma cells (48). These particles exhibit RT activity and contain
mature forms of the Gag and Env proteins. In addition, the pol gene and Gag, Env, and
Rec proteins are expressed in human melanomas and metastases but not in melanocytes
or normal lymph nodes, suggesting that expression of retroviral genes/ proteins and
production of retroviral particles is activated during development of melanoma (48).
Later, Büscher et al. demonstrated that these particles contain deletions and are
noninfectious. They also found antibodies against HERV-K, for the first time, in
melanoma patients, and concluded that melanoma is associated with enhanced
expression of HERV-K (36). The same group later investigated the expression of Rec,
Np9, and TM in melanoma cells, and came to the conclusion that they had expression
patterns similar to those seen in teratocarcinoma cell lines (71).
To search for a melanoma marker, Humer et al. identified an immunodominant
peptide located in the Env protein of HERV-K from bioinformatic screening, and their
results suggest the potential of the peptide as a target for diagnosis and immunotherapy
(72). Silvia Hahn et al studied the serological response to HERV-K Gag and Env protein
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in patient sera to elucidate the prognostic relevance of serological anti-HERV-K
reactivity in melanoma patients and correlate with survival probability. Indeed they
found the correlation, suggesting that humoral anti-HERV-K immune response may
provide additional prognostic information for melanoma (73).
Using RNA interference (RNAi) specific to HERV-K, two groups revealed potential
roles of HERV-K in melanoma. Oricchio et al. found that with down-regulated HERV-K
expression by RNAi in the melanoma cell line A375, the in vivo tumorigenic potential of
the interfered cells was reduced after inoculation of the cells in nude mice, although the
in vitro cell proliferation and differentiation remained unchanged (74). Serafino et al.
found that when exposed to stress conditions, human melanoma cells undergo a
transition in vitro from adherent to a more malignant, non-adherent phenotype, with an
increased proliferative potential, and that his transition was accompanied by the
activation of HERV-K and massive production of viral-like particles. In addition, downregulation of HERV-K expression by RNAi prevents the transition in low serum (75).
These results implicate HERV-K as playing a critical role at least during melanoma
progression.
Environmental factors have also been used to study the association between HERVK and melanoma. UV irradiation can induce differential expression of rec and np9
transcripts in primary human melanocytes and melanoma cell lines (76); it can also
induce a significant activation of HERV-K pol gene as well as an enhanced expression of
Kenv protein in melanoma cell lines, but not in non-melanoma cells (77). These findings
indirectly suggest the involvement of HERV-K in melanoma.
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It is not fully understood how HERV-K expression is regulated in melanoma, and
recently some studies have been addressing this question. Stengel et al. investigated the
epigenetic regulation of HERV-K in melanoma, and found that increased HERV-K
expression in melanomas may be due to increased promoter activity and demethylation
of the 5'LTR (78). Li et al. found that in melanoma cells, expression of HERV-K
correlates with status of MEK-ERK and p16INK4A-CDK4 pathways in melanoma cells,
and inhibition of MEK or CDK4, especially in combination, reduced Kenv expression
(79). Katoh et al. found that MITF-M, a melanocyte/melanoma-specific isoform of
microphthalmia-associated transcription factor (MITF), could activate the pigmented cell
lineage-specific function of HERV-K LTR, leading to the high-level expression of
HERV-K in malignant melanoma (80). These findings provide some molecular
mechanisms for the regulation of HERV-K expression in melanoma.
Most recently, according to analysis of HERV-K loci transcription in melanoma,
unlike Gag, the Env-coding loci with ORFs are only transcribed in melanoma, but not in
normal melanocytes, suggesting the involvement of Env protein in melanoma (81).
Huang et al. observed that when HERV-K expression was reduced using RNAi and antiKenv monoclonal antibodies, dramatic reduction of intercellular fusion of cultured
melanoma cells occured, revealing the novel fusogenic function of Kenv protein in
melanoma cells (82). These findings suggest that Kenv protein could play important
roles in melanoma.
1.2.4

HERV-K and human pancreatic cancer

Pancreatic cancer is one of the most deadly cancer types. In the US, pancreatic cancer
is the 10th most common cancer among men and the 9th most common among women,
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and it accounts for about 7% of all cancer deaths and ranks fourth as a cause of cancer
death among both men and women. In 2013, an estimated 45,220 new cases of
pancreatic cancer will be diagnosed nationwide, with an estimation of about 38, 460
pancreatic cancer deaths. Most pancreatic cancer patients will die within the first year of
diagnosis, and the five-year survive rate is only 6% (54).
Pancreatic cancer is considered as a silent killer because early pancreatic cancer often
does not cause symptoms, and the symptoms at later stages are usually non-specific and
varied, resulting in late diagnosis and consequently an exceptionally low survival rate.
The lack of progress in primary prevention, early diagnosis, and treatment underscores
the need for additional efforts in pancreatic cancer research. Since pancreatic cancer is so
deadly, any new agents that can improve patient survival by improving its detection or
treatment could revolutionize clinical practice (54).
There has been no direct evidence linking HERV-K and human pancreatic cancer.
However, when seeking to identify novel cancer testis antigens in pancreatic cancer for
immunotherapy applications, Schmitz-Winnenthal et al. found that HERV-K-MEL is
expressed in 23% of malignant, but not in non-malignant, pancreatic tissues (83).
Considering the fact that HERV-K-MEL is a partial Kenv sequence, this study could
implicate that Kenv be specifically expressed in human pancreatic cancer. In fact, our
group recently investigated HERV-K expression in human pancreatic cancer. In our
studies, using RT-PCR and sequence analysis, Kenv mRNAs were found to be expressed
in seven pancreatic cancer cell lines as well as in 80% of pancreatic cancer xenograft
biospies, but not in HPDE-E6E7 nonmalignant cells. The expression profile of Kenv
proteins, characterized via using an anti-HERV-K mAb, revealed HERV-K expression in
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pancreatic cancer cells and specimens but not in HPDE-E6E7 cells or matched adjacent
uninvolved normal tissues. Higher RT activity was observed in culture media obtained
from Panc-2, Panc-1, and Colo-357 cells than in media from other pancreatic cancer cell
lines and HPDE-E6E7 cells. Furthermore, Kenv or gag mRNA expression, as well as the
titer of antibody against Kenv SU or Np9, was significantly higher in sera obtained from
pancreatic cancer patients than from normal donors. Our data indicate that HERV-K
genes are transcribed, translated, and able to produce viral particles in some pancreatic
cancer cell lines and sera obtained from pancreatic cancer patients. Our results also
demonstrate that HERV-K viral protein or viral particles have characteristics of tumorassociated antigens, and are potentially useful targets for detection, diagnosis and
immunotherapy of pancreatic cancer (manuscript submitted for publication).
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Chapter 2 Statement of Objectives
Although published data have suggested the tight association between HERV-K
expression and multiple human cancers, the causal relationship between the two is still
unclear, and it is even uncertain which HERV-K gene/ protein could play a critical role
in this association. However, the transition of melanoma cells under stress could not be
accomplished with down-regulation of HERV-K, suggesting the critical involvement of
HERV-K in melanoma transformation.
As mentioned above, expression of Kenv protein has been observed in multiple
human cancers, including breast cancer, melanoma and pancreatic cancer, but not in
normal tissue or normal cell lines. In addition, Kenv protein can trigger a serologic
response in patients with all the three of these cancer types. Importantly, Kenv protein
antibodies exhibit antitumor potential in targeting breast tumors, indicating that Kenv
may play an important role in carcinogenesis or tumor progression. However, the actual
role of Kenv protein in cancer is still to be confirmed. Based on all the previous findings,
I hypothesized that the Kenv protein may be involved in the processes of
proliferation, migration and invasion associated with multiple human cancers, and
that the Kenv protein may play an important functional role as an oncogene in
multiple human cancers. In this project, I studied the role of Kenv protein in human
breast cancer, pancreatic cancer and melanoma, using both over-expression and
knockdown approaches, and tried to address the mechanism underlying the role of Kenv.
To address my hypothesis, I proposed three Specific Aims:

30

1. To determine the effect of knockdown of Kenv protein using RNAi on human
cancer cell growth and tumorigenic potential. An Kenv-specific shRNA (shRNAenv),
as well as a corresponding scrambled control shRNA (shRNAc), was constructed in a
shRNA-expressing lentivector and stably transduced into multiple human cancer cell
lines. The mRNA and protein levels of Kenv were evaluated after transduction, and the
proliferation, colony formation and cell migration potential of the transduced cells were
determined in vitro and in vivo.
2. To characterize Kenv protein expression and function in stably-transfected
human cell lines. A lentivector that can express Kenv protein in mammalian cells was
constructed (pLVX-Kenv), and the empty lentivector was used as control (pLVX). The
pLVX-Kenv or pLVX vector was stably transduced into the premalignant human breast
epithelial cell line MCF10AT, as well as cancer cell lines that included MCF-7 and
SKBR-3. The mRNA and protein levels of Kenv were evaluated after transduction, and
the proliferation, colony formation and migration potential of the transduced cells were
determined in vitro and in vivo.
3. To determine the role(s) of Kenv protein in mechanistic pathways involved in
multiple human cancers. Xenograft HERV-K knockdown tumors growing in
immunodeficient mice were subjected to RNA Seq analysis, and the results were
analyzed by Ingenuity Pathway Analysis (IPA) for the presence of gene networks that
would explain the changes in gene expression that we observed in the tumors. Some
preliminary validation of the IPA results was done, and further work needs be carried out
to complete the verification of changes in expression of signaling pathway proteins in
response to HERV-K knockdown in these cancer cells and tumors.
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Chapter 3 Materials and Methods
3.1 Cell lines and animals
Human breast cancer cell lines SKBR-3, MCF-7 and MDA-MB-231, human
pancreatic cancer cell lines Panc-1 and Panc-2, and human melanoma cell line A375 and
SK-MEL28 were obtained from the American Type Culture Collection (ATCC,
Manassas, VA). The human breast cancer cell line MDA-MB-435 eB1, which was
established from MDA-MB-435 by transfecting with c-erbB-2 cDNA, and which
overexpresses v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/
glioblastoma derived oncogene homolog (avian) (ERBB2), was a kind gift from Dr.
Michael Rosenblum (The University of Texas MD Anderson Cancer Center, Houston,
TX). The premalignant human breast cell line MCF-10AT, an H-Ras-transformed variant
of the human breast epithelial cell line MCF-10A, was purchased from The Barbara Ann
Karmanos Cancer Institute (Detroit, MI). 293TN, which is a variant of 293T and is
optimized for optimized for pseudoviruses production, was purchased from System
Biosciences (SBI, Mountain View, CA). 293FT, similar to 293TN, was a kind gift from
Dr. Dean Tang (The Virginia Harris Cockrell Cancer Research Center at The University
of Texas MD Anderson Cancer Center, Smithville, TX). MCF-7, MDA-MB-231 and
SK-MEL-28 were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium
supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin; MCF10AT was cultured in Dulbecco’s Modified Eagle Medium: Ham’s Nutrient Mixture F12
(DMEM:F12) medium supplemented with 5% horse serum, 100 U/ml penicillin, 100
μg/ml streptomycin, 10 μg/ml insulin, 20 ng/ml epidermal growth factor and 0.5 μg/ml
hydrocortisone; all other cell lines were cultured in DMEM medium supplemented with
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10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin.
Immunocompromised nude and NOD-SCID gamma (NSG) mouse stains were used
in xenograft tumor model studies. Nude mice were purchased from NCI at Frederick
(Frederick, MD). NSG mice were a generous gift from Dr. Dean Tang.
3.2 Lentivector construction and packaging
A short hairpin RNA (shRNA) sequence targeting the HERV-K env (GenBank No.
M14123.1) SU region (shRNAenv) and a matched scrambled shRNA sequence serving
as negative controls (shRNAc) were designed using the Invitrogen Block-iT RNAi
Designer. For each shRNA, two partial-matching oligonucleotides, both containing the
shRNA sequence, were designed, synthesized, annealed and then cloned into the
pGreenPuro™ vector (SBI) as shown in Figure 6. The shRNA-expressing lentiviral
particles were packaged using a pPACKH1 Lentivector Packaging Kit (SBI), and then
the virus particles were titered using 293TN cells, following the manufacturer’s manual.
A Kenv-expressing vector (pLVX-Kenv) was constructed from lentivector pLVXdsRed-Monomer-C1 (pLVX) (Clontech Laboratories, Mountain View, CA), as shown in
Figure 7. cDNA of a full-length Kenv was de novo synthesized based a sequence
obtained from plasma of a breast cancer patient. The sequence, which showed high
homology to HERV-K50A provirus (GenBank Accession Number: DQ112146), was
then cloned into the lentivector by Biomatik (Cambridge, Ontario, Canada). The Kenvexpressing lentiviral particles were then packaged and titered in 293FT cells according to
the instructions of the manufacturer of the vector. The lentiviral particles generated from
pLVX vector were used as negative controls.
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HERV-K Env
SU

TM

shRNAenv

shRNAv

Figure 6. Construction of shRNA-expressing lentivector. A shRNA sequence targeting
the HERV-K env SU region (shRNAenv) and a matched scrambled shRNA sequences
serving as negative controls (shRNAc) were cloned into the lentivector vector
pGreenPuro at EcoRI and BamH I restriction enzyme sites..
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Full‐length HERV‐K env from patient
SU

TM

pLVX‐Kenv

Figure 7. Construction of Kenv-expressing lentivector pLVX-Kenv. A Kenv sequence
obtained from plasma of a breast cancer patient was cloned into lentivector pLVXDsRed-Monomer-C1 (pLVX) at BsaI (insert)/EcoRI (vector) and XmaI restriction
enzyme sites. Lentivector pLVX was used as negative control.
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3.3 Lentivector transduction
100,000 cells were seeded into each well and grown in 6-well plates and then
transduced with the lentiviral particles at a multiplicity of infection (MOI) of 40. After
three days, cells were transferred into T25 flasks and cultured in media containing 0.2
μg/ml of the selective drug puromycin. After at least two weeks post transduction, the
stably-selected cells were used in various assays.
3.4 RT-PCR and qRT-PCR
RNA was isolated from cells or tumor biopsy specimens using TRI reagent (SigmaAldrich, St. Louis, MO), and cDNAs of Type 1 and Type 2 Kenv SU were amplified by
RT-PCR as described previously (64, 65). The cDNA of β–actin was amplified as a
positive control and used to confirm equal loading of samples. Ready-to-Go You-Prime
First-Strand Beads (GE Healthcare, Pittsburgh, PA) were used to synthesize cDNA from
10 µg RNA, and 1 µg RNA was used in each PCR reaction. Primers K10 OS and K10
OAS were used to amplify cDNA of Type 1 Kenv SU, and primers K22 OS and K10
OAS were used to amplify cDNA of Type 2 Kenv SU (Table 3). The PCR was carried
out on a DNA Engine (PTC-200, Bio-Rad) thermocycler using the following program:
95 oC for 3 min, 35 cycles of 94 oC for 1min, 55 oC for 1min, 72 oC for 1 min, and a final
10 min extension at 72 oC.
The mRNA levels of Kenv in different cell lines or xenograft tumors were quantified
and compared by quantitative RT-PCR (qRT-PCR) using Kenv-specific primers and
probes as described previously (65) (Table 3). Generally, qRT-PCT was carried out
using the TaqMan® One-Step RT-PCR Master Mix Reagents Kit (Life Technologies,
Grand Island, NY) in a 7900HT Real-time PCR instruments (Life Technologies, Grand
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Island, NY) using the following program: 48 °C for 30 minutes, 95 °C for 15 minutes,
and then 40 cycles of 15 seconds at 95 °C and 1 minutes at 60 °C. After the qRT-PCR
reaction was completed, the mRNA levels of Kenv in different RNA samples were
compared using the delta-delta Ct method, with normalization to that of an endogenous
control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Life Technologies, Grand
Island, NY).
To validate the RNA Seq results, a two-step qRT-PCR was carried out. After cDNA
synthesis using the RTG beads as described above, the cDNAs of shRNA transduced
cells were used as template, and the genes involved in the mevalonate pathway were
tested using the SYBR® Green PCR Master Mix (Life Technologies, Grand Island, NY)
and the primers described in Table 3.
3.5 Immunoblot analysis
Total protein lysates of cells were used for immunoblot analysis (~50 µg of protein
per lane) as described previously (29, 30). Anti-Kenv mAb (6H5) (~1 μg/ml) and antiactin (ACTB) antibodies (1:200 dilution; University of Iowa, Iowa City, IA) were used
as primary antibodies, with anti-mIgG-horseradish peroxidase conjugates (1:5000
dilution; Sigma-Aldrich, St. Louis, MO) serving as the secondary antibody.
3.6 Cell proliferation
1 x 104 cells/well were plated in complete medium in a 24-well plate and incubated at
37 °C. Cells were then trypsinized at different time points, and cell proliferation rates
were measured by counting number of viable cells using the trypan blue dye exclusion
method.
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Primers

Sequences

For RT-PCR:
K10 OS

5′-AGAAAAGGGCCTCCACGGAGATG-3’

K10 OAS

5′-ACTGCAATTAAAGTAAAAATGAA-3’

K22 OS

5'-GTATGCTGCTTGCAGCCTTGATGAT-3’

Actin OS

5’-TGACGGGGTCACCCACACTGTGCC-3’

Actin OAS

5’-CTAGAAGCATTTGCGGTGGACGAT-3’

For one-step qRT-PCR:
Kenv Forward

5'-ATTGGCAACACCGTATTCTGCT-3'

Kenv Reverseev

5'-CAGTCAAAATATGGACGGATGGT-3'

Kenv Probe

5'-FAM-ACACAGGGATCCACACGCCCTCTCTT-TAMRA-3'

For two-step qRT-PCR
RPL32 Forward

5'-TTCCTGGTCCACAACGTCAAG-3'

RPL32 Reverse

5'-TGTGAGCGATCTCGGCAC-3'

ACAT2 Forward

5'-GCGGCGCGGACCAT-3'

ACAT2 Reverse

5'-CCTGGACAGGAACAGCAGCTA-3'

HMGCS1 Forward

5'-GGGCAGGGCATTATTAGGCTAT-3'

HMGCS1 Reverse

5'-TTAGGTTGTCAGCCTCTATGTTGAA-3'

HMGCR Forward

5'-GGCCCAGTTGTGCGTCTT-3'

HMGCR Reverse

5'-CGAGCCAGGCTTTCACTTCT-3'

MVD Forward

5'-TGAACTCCGCGTGCTCATC-3'

MVD Reverse

5'-CGGTACTGCCTGTCAGCTTCT-3'

IDI1 Forward

5'-TTTCCAGGTTGTTTTACGAATACG-3'

IDI1 Reverse

5'-TCCTCAAGCTCGGCTGGAT-3'

SQLE Forward

5'-CGTGCTCCTCTTGGTACCTCAT-3'

SQLE Reverse

5'-CGGTCAAGGCGGAGATTATC-3'

CYP51A1 Forward

5'-TGCAGCCTGGCTCTTACCA-3'

CYP51A1 Reverse

5'-AGCTCTGTCCCTGCGTCTGA-3'

DHCR24 Forward

5'-CAAGTACGGCCTGTTCCAACA-3'

DHCR24 Reverse

5'-CGCACAAAGCTGCCATCA-3'

Table 3. Sequences of primers and probe used in RT-PCR and qRT-PCR assays. All the
primer were synthesized by Integrated DNA Technologies (IDT, Coralville, IA), and
probe was synthesized by Life Technologies (Grand Island, NY). The sequences of the
primers used in the two-step qRT-PCR are obtained from reference (84).
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3.7 Anchorage-independent colony formation assay (soft agar assay)
Anchorage-independent growth of lentivector-transduced cells was tested according
to a published method (85). Briefly, 2 ml culture medium with 0.7% agar was first plated
into each well of a 6-well plate. After the bottom agar solidified, each well received
another 1 ml 0.35% agar in culture medium carrying 5, 000 cells. Colonies were counted
after 2 to 3 weeks of incubation.
3.8 Time-lapse wound-healing assay
shRNA transduced cells were plated in 6-well plates. Cells were cultured until
reaching confluence, and then the confluent monolayer was scratched using a plastic
pipette tip and replaced with fresh medium. Sequential and single images were acquired
at different time points (up to 48 hours) and were assembled.
3.9 Trans-well plate assay
For migration assay, 24-well plates with transwell permeable supports (Fisher
Scientific, Hampton, NH) were used. Cells were trypsinized, counted and suspended in
serum-free medium at a dilution of 2.5x 105/ml. 200 μl serum-free medium with
suspended cells was placed into the upper chamber, and 750 μl complete medium was
placed into the bottom chamber. The plate was incubated at 37 oC for 16-40 hours, until
some cells attached and grew in the bottom chamber. The medium was removed and the
chambers were washed twice with phosphate buffered saline (PBS). The cells were then
fixed with formaldehyde (3.7% in PBS, 1 ml/ well) at room temperature for 2 minutes,
washed twice with PBS, and permeabilized with 100% methanol at room temperature for
20 minutes. After fixation and permeabilization, the cells were washed twice, stained
with Giemsa at room temperature for 15 minutes, washed twice again and rinsed with
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PBS. The cells in the bottom chamber were counted as migrated cells under a
microscope.
The invasion assay was carried out in a manner similar to the migration assay, with
some modifications: Before the transwell plate was used, 100 μl Matrigel (BD
Biosciences, San Jose, CA) was added to each upper chamber, and the plate was
incubated at 37 oC overnight to allow gelling. After staining, adherent cells in the upper
chamber were scraped off with cotton swabs, and the cells adhering to the bottom of the
upper chamber were counted as invaded cells under a microscope.
3.10 In vivo studies
To assess tumorigenesis and phenotypes of lentivector-transduced cells in vivo, 6-8
week old female nude or NSG mice, were inoculated subcutaneously under the fourth
mammary gland (the breast cell lines) or in the flank (all other cell lines) with 1 × 106
cells transduced with shRNAenv or shRNAc to assess tumorigenesis and phenotypes of
these cells in vivo. Tumors were harvested in accordance with IACUC animal welfare
indications and compared by weight. H&E staining was used to provide histologic
evidence of malignancy. RNAs and proteins were isolated from both groups and the
expression of Kenv was determined by qRT-PCR/RT-PCR and immunoblot. To
determine the metastatic potential of shRNA transduced MDA-MB-231 and Panc-2 cells,
lung tissues were collected post-mortem and cultured in the same media as parent cells.
Metastatic MDA-MB-231 or Panc-2 cells isolated from lung were compared between the
two groups.
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3.11 RNA Seq analysis
For RNA Seq, the quality of isolated total RNA isolated from the xenograft tumors
was verified on a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). RNA
samples with an RNA Integrity Number above 8.0 were used in the RNA Seq
experiment. cDNA libraries were synthesized from 100 ng input RNA using NuGen’s
Ovation RNA Seq System (NuGEN Technologies, San Carlos, CA), following the
manufacturer’s guidelines. After shearing the cDNA into 150-400 bp fragments on a
Covaris S220 (Covaris, Woburn, MA), these fragments were ligated and indexed with
Bioo Adapter 100 (Bioo Scientific, Austin, TX) on a SPRIworks Fragment Library
System (Beckman Coulter, Brea, CA). The adapter-ligated cDNA fragments were sizeselected and cleaned up on SPRIworks, and quality checked by both Bioanalyzer and
qPCR on a 7900HT Fast Real-time PCR System (Life Technologies, Grand Island, NY).
Libraries from 6 RNA samples were pooled and hybridized to primers on a flow cell for
cluster generation on an Illumina cBot (Illumina, San Diego, CA). A 76 nt paired-end
run was performed on an Illumina HiSeq 2000. Sequencing data were transmitted to
either an HP DL385 or HP DL585 computer server in real-time and stored in an HP
P2000 data storage array on-site at MD Anderson – Science Park (Smithville, TX). For
mRNA Seq data analysis, to rescue the reads over splice junctions, the sequenced reads
were mapped to the mouse or human reference genomes by the splice junction aligner
TopHat (86). The number of reads in each known gene from the RefSeq database (87)
(mRNA Seq) were enumerated and the difference of read counts per gene between
samples (i.e., differential expression) was statistically assessed by R/Bioconductor
package edgeR (88) or DESeq (89). Networks of differentially expressed genes were
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identified using Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Inc., Redwood
City, CA).
3.12 Statistical analysis
All statistical tests were two-sided, and differences between variables with a P value
of <0.05 were considered statistically significant. We used t-tests to analyze differences
between treatment groups in cell culture experiments using GraphPad Prism 5.
3.13 Ethics Statement:
All mouse experiments were approved by the Institutional Animal Care and Use
Committees (IACUC, protocol number 01-04-00733) of the University of Texas MD
Anderson Cancer Center. Mice were housed in a temperature-, humidity-, and lightcontrolled room and fed a sterile regular diet. The ventilated caging housing system
consists of a polycarbonate or polysulfone cage, a polycarbonate or polysulfone filter lid
with woven-fiber filter media, and a stainless steel wire-bar lid. The individual cages are
maintained on a HEPA-filtered, ventilated, suspended cage-type rack. Per institutional
practice, the maximum mouse population per mouse cage is 5 adult mice of any size or
age. For euthanasia, mice were placed in a chamber filled with CO2 and after breathing
stopped and the mice were unconscious, euthanasia was completed by cervical
dislocation. Tumors were excised on the final day of the study. The tumor tissues were
dissected, transferred to 10% neutral buffered formalin (Fisher Scientific, Hampton,
NH), and embedded into paraffin blocks. Five micrometer thick formalin-fixed and
paraffin-embedded biopsy sections were used for histological diagnosis, the expression
of HERV-K, and other assays.
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This study was carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health. All
animal facilities of The University of Texas MD Anderson Cancer Center are under the
direction of full-time veterinarians and are fully accredited by the American Association
of Accreditation of Laboratory Animal Care. The University of Texas MD Anderson
Cancer Center complies with the National Institutes of Health’s policy on animal
welfare, the Animal Welfare Act and all applicable federal, state and local laws.
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Chapter 4 Results
4.1 Down-regulation of Kenv expression in multiple human cancer cell lines by
shRNA knockdown
Fluorescence microscopy was used to determine the transfection efficiency in various
human cancer cell lines transduced with lentiviral particles harboring shRNAenv or
shRNAc bearing a green fluorescent protein (GFP) reporter. All cells expressed GFP
after drug selection (data not shown). The cells were harvested for RNA isolation or
lysed for immunoblot analysis after at least two weeks post transduction. The expression
of Kenv mRNA and protein was partially downregulated in cells transduced with
shRNAenv, compared with expression in cells transduced with shRNAc, as assessed by
RT-PCR, qRT-PCR, or immunoblot assay using 6H5 mAb (Figures 8-13). A
significantly reduced expression of HERV-K env RNA was observed in MDA-MB-231
(p = 0.0004), MDA-MB-435 eB1 (p = 0.0009), SKBR-3 (p = 0.0055), Panc-2 (p =
0.0318), Panc-1 (p= 0.0221) and A375 (p = 0.0057) cells compared with cells transduced
with shRNAc, as assessed by qRT-PCR, and this reduction was confirmed in all cell
lines by RT-PCR. A reduced expression of Kenv protein was also observed by
immunoblot in all cell lines transduced with shRNAenv, compared with shRNAc
(Figures 8-13).
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Figure 8. Down-regulation of Kenv expression in MDA-MB-231 by shRNA
knockdown. Reduced expression of Kenv mRNA was demonstrated in MDA-MB-231
cells transduced with Kenv shRNA (shRNAenv) compared with control shRNA
(shRNAc) (left panel). The significantly reduced expression of HERV-K env RNA
determined by qRT-PCR (p = 0.0004) was confirmed by RT-PCR (top right panel).
Furthermore, the reduced expression of Kenv at the protein level was demonstrated by
immunoblot assay using 6H5 mAb (bottom right panel).
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Figure 9. Down-regulation of Kenv expression in MDA-MB-435 eB1 by shRNA
knockdown. Reduced expression of Kenv mRNA was demonstrated in MDA-MB-435
eB1 cells transduced with Kenv shRNA (shRNAenv) compared with control shRNA
(shRNAc) (left panel). The significantly reduced expression of HERV-K env RNA
determined by qRT-PCR (p = 0.0009) was confirmed by RT-PCR (top right panel).
Furthermore, the reduced expression of Kenv at the protein level was demonstrated by
immunoblot assay using 6H5 mAb (bottom right panel).
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Figure 10. Down-regulation of Kenv expression in SKBR-3 by shRNA knockdown.
Reduced expression of Kenv mRNA was demonstrated in SKBR-3 cells transduced with
Kenv shRNA (shRNAenv) compared with control shRNA (shRNAc) (left panel). The
significantly reduced expression of HERV-K env RNA determined by qRT-PCR (p =
0.0055) was confirmed by RT-PCR (top right panel). Furthermore, the reduced
expression of Kenv at the protein level was demonstrated by immunoblot assay using
6H5 mAb (bottom right panel).
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Figure 13. Down-regulation of Kenv expression in A375 by shRNA knockdown.
Reduced expression of Kenv mRNA was demonstrated in A375 cells transduced with
Kenv shRNA (shRNAenv) compared with control shRNA (shRNAc) (left panel). The
significantly reduced expression of HERV-K env RNA determined by qRT-PCR (p =
0.0057) was confirmed by RT-PCR (top right panel). Furthermore, the reduced
expression of Kenv at the protein level was demonstrated by immunoblot assay using
6H5 mAb (bottom right panel).
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4.2 Knockdown of Kenv inhibited cancer cell proliferation and transformation
In the cell proliferation assay, all cancer cell lines transduced with shRNAenv had a
significantly reduced proliferation rate compared to those transduced with shRNAc
(Figures 14-19A), after 2 to 3 weeks of transduction. Furthermore, a soft agar assay
showed significantly reduced colony formation in shRNAenv transduced cells compared
with shRNAc transduced cells (Figures 14-19 B&C).
4.3 Knockdown of Kenv inhibited migration of some cancer cell lines in vitro
To investigate the influence of Kenv knockdown on migration rate of the cancer cell
lines in vitro, a time-lapse wound-healing assay was carried out. With transduction of
shRNAenv, MDA-MB-231, MDA-MB-435 eB1 and A375 cells showed slower woundhealing rate than the control cells, indicating that the in vitro migration rate of the three
cell lines was inhibited by knockdown of Kenv (Figures 20, 21&25). However, the
wound-healing rate of SKBR-3, Panc-2 and Panc-1 transduced with shRNAenv did not
show apparent differences from that of the control cells, indicating that their in vitro
migration rate was not influenced by knockdown of Kenv (Figures 22-24).
A transwell plate assay was also used to assess the influence of Kenv knockdown on
migration rate, as well as invasion rate, of MDA-MB-231, SKBR-3 and A375 in vitro. In
the migration assay plate, a smaller number of shRNAenv transduced MDA-MB-231,
SKBR-3 and A375 cells than of control cells were observed in the bottom chamber,
again indicating that the in vitro migration rate was inhibited by knockdown of Kenv. In
addition, an invasion plate assay showed that a smaller number of shRNAenv transduced
MDA-MB-231 and A375 cells than control cells were found under the bottom chamber,
indicating a slower invasion rate result from knockdown of Kenv (Figure 26).
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Figure 14. Inhibition of cell proliferation and colony formation of MDA-MB-231 cells
by shRNAenv. A. MDA-MB-231 cells transduced with shRNAenv have a significantly
decreased proliferation rate than those transduced with shRNAc; B. In the anchorageindependent colony formation assay, the colony-formation potential of MDA-MB-231
was significantly inhibited by shRNAenv (p = 0.0034); C. Representative pictures of
colonies formed from MDA-MB-231 cells transduced with shRNAc or shRNAenv.
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Figure 15. Inhibition of cell proliferation and colony formation of MDA-MB-435 eB1
cells by shRNAenv. A. MDA-MB-435 eB1 cells transduced with shRNAenv have a
significantly decreased proliferation rate than those transduced with shRNAc; B. In the
anchorage-independent colony formation assay, the colony-formation potential of MDAMB-435 eB1 was significantly inhibited by shRNAenv (p = 0.0046); C. Representative
pictures of colonies formed from MDA-MB-435 eB1 cells transduced with shRNAc or
shRNAenv.
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Figure 16. Inhibition of cell proliferation and colony formation of SKBR-3 cells by
shRNAenv. A. SKBR-3 cells transduced with shRNAenv have a significantly decreased
proliferation rate than those transduced with shRNAc; B. In the anchorage-independent
colony formation assay, the colony-formation potential of SKBR-3 was significantly
inhibited by shRNAenv (p = 0.0039); C. Representative pictures of colonies formed from
SKBR-3 cells transduced with shRNAc or shRNAenv.
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Figure 17. Inhibition of cell proliferation and colony formation of Panc-2 cells by
shRNAenv. A. Panc-2 cells transduced with shRNAenv have a significantly decreased
proliferation rate than those transduced with shRNAc; B. In the anchorage-independent
colony formation assay, the colony-formation potential of Panc-2 was significantly
inhibited by shRNAenv (p = 0.0104); C. Representative pictures of colonies formed from
Panc-2 cells transduced with shRNAc or shRNAenv.
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Figure 18. Inhibition of cell proliferation and colony formation of Panc-1 cells by
shRNAenv. A. Panc-1 cells transduced with shRNAenv have a significantly decreased
proliferation rate than those transduced with shRNAc; B. In the anchorage-independent
colony formation assay, the colony-formation potential of Panc-1 was significantly
inhibited by shRNAenv (p = 0.0073); C. Representative pictures of colonies formed from
Panc-1 cells transduced with shRNAc or shRNAenv.
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Figure 19. Inhibition of cell proliferation and colony formation of A375 cells by
shRNAenv. A. A375 cells transduced with shRNAenv have a significantly decreased
proliferation rate than those transduced with shRNAc; B. In the anchorage-independent
colony formation assay, the colony-formation potential of A375 was significantly
inhibited by shRNAenv (p = 0.0016); C. Representative pictures of colonies formed from
A375 cells transduced with shRNAc or shRNAenv.
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Figure 20. Time-lapse wound-healing assay of shRNA transduced MDA-MB-231 cells.
The wound of shRNAenv transduced MDA-MB-231 cells healed slower, indicating a
decreased migration rate in vitro.
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Figure 21. Time-lapse wound-healing assay of shRNA transduced MDA-MB-435 eB1
cells. The wound of shRNAenv transduced MDA-MB-435 eB1 cells healed slower,
indicating a decreased migration rate in vitro.
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Figure 22. Time-lapse wound-healing assay of shRNA transduced SKBR-3 cells. The
wound-healing rate of the two shRNA transduced SKBR-3 cells did not exhibit an
apparent difference, indicating a similar migration rate in vitro.
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Figure 23. Time-lapse wound-healing assay of shRNA transduced Panc-2 cells. The
wound-healing rate of the two shRNA transduced Panc-2 cells did not exhibit an
apparent difference, indicating a similar migration rate in vitro.
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Figure 24. Time-lapse wound-healing assay of shRNA transduced Panc-1 cells. The
wound-healing rate of the two shRNA transduced Panc-1 cells did not exhibit an
apparent difference, indicating a similar migration rate in vitro.
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Figure 25. Time-lapse wound-healing assay of shRNA transduced A375 cells. The
wound of shRNAenv transduced A375 cells healed slower, indicating a decreased
migration rate in vitro.
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4.4 Knockdown of Kenv reduced tumor growth in xenograft models
To investigate the potential effect of Kenv on the growth of cancer cell lines in vivo,
SKBR-3, Panc-2 or Panc-1 cells transduced with shRNAenv or shRNAc were
subcutaneously injected into nude mice to generate human tumor xenografts. Reduced
growth of tumor xenografts were observed when the cells were transduced with
shRNAenv, and in particular, the reduction is significant (p = 0.0074) with regard to
Panc-1 cells (Figures 27-29). It is noteworthy that not every injection resulted an
xenograft tumor (eg. 7 out of 10 injections of shRNAenv tranduced Panc-2 resulted in
xenograft tumor growth, while 5 out of 10 injections of shRNAc tranduced Panc-2
resulted in xenograft tumor growth) , and the tumor size varied a lot even in the same
experimental group.
Further, MDA-MB-231, MDA-MB-435 eB1, SKBR-3, Panc-2 or A375 cells
transduced with shRNAenv or shRNAc were subcutaneously injected into NSG mice to
generate human tumor xenografts. Growth curves of these xenografts over 3-8 weeks
showed that the shRNAenv transduced groups displayed a significantly lower growth
rate compared to control groups (Figures 30-34 A). Tumor sizes and weights were
significantly reduced in NSG mice harboring cancer cells transduced with shRNAenv
compared with control mice (Figures 30-34 B). H&E staining showed no significant
changes in histology of tumor biopsies from either groups, except that the control tumors
appeared to have more tumor necrosis, possibly due to a less blood supply to tumor mass
ratio (an example was shown in Figure 35).
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Figure 27. Inhibition of growth of SKBR-3 xenograft tumors in nude mice by
shRNAenv transduction. Smaller tumor sizes (left panel) and reduced tumor weights
(right panel) were observed when SKBR-3 cells transduced with shRNAenv were grown
as xenografts, compared with control cells.
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Figure 28. Inhibition of growth of Panc-2 xenograft tumors in nude mice by shRNAenv
transduction. 5 out of 10 injections of shRNAenv tranduced Panc-2 resulted in xenograft
tumor growth, while 7 out of 10 injections of shRNAc tranduced Panc-2 resulted in
xenograft tumor growth. Smaller tumor sizes (left panel) and reduced tumor weights
(right panel) were observed when Panc-2 cells transduced with shRNAenv were grown
as xenografts, compared with control cells.
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Figure 29. Inhibition of growth of Panc-1 xenograft tumors in nude mice by shRNAenv
transduction. 9 out of 10 injections of shRNAenv tranduced Panc-1 resulted in xenograft
tumor growth, while 7 out of 10 injections of shRNAc tranduced Panc-1 resulted in
xenograft tumor growth. Smaller tumor sizes (lower panel) and significantly reduced
tumor weights (p = 0.0074, upper panel) were observed when Panc-2 cells transduced
with shRNAenv were grown as xenografts, compared with control cells.
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Down-regulation of Kenv mRNA expression in the tumor biopsies of MDA-MB-231,
MDA-MB-435 eB1, Panc-2 and A375 was further confirmed by RT-PCR and qRT-PCR,
respectively (Figures 36-39), and down-regulation of Kenv protein expression in the
A375 tumor biopsies was also confirmed by immunoblot (Figure 39).
Of interest, GFP+ Panc-2 cells were observed in dissociated and cultured lung tissues
collected from control shRNAc mice, but were strikingly absent in lung tissues of
shRNAenv mice (Figure 40). The same observation can be found in the sections of the
lung tissues (Figure 41). Similar results was observed in the case of shRNA transduced
MDA-MB-231, but the GFP+ MDA-MB-231 cell numbers were fewer, instead of absent,
in the lung tissues of shRNAenv mice (Figure 42&43). This finding suggests a role for
Kenv in enabling the formation of distant metastases.
4.5 Differential gene expression profiling by RNA-Seq and IPA
We performed whole genome RNA-Seq analysis of xenografts from transduced
SKBR-3, Panc-2, Panc-1 and A375, as well as of the transduced MDA-MB-435
eB1cells. The results were subjected to IPA analysis to identify the Kenv-related
networks of differentially expressed genes in our samples. A brief summary for each pair
of shRNAenv/shRNAc xenografts or cells is shown in Tables 4-9, and an overall
summary across all samples is shown in Table 10. In common, Cancer, Gastrointestinal
Disease and Dermatological Diseases and Conditions are the top three diseases and
disorders related to Kenv; Kenv is highly related to several molecular and cellular
functions: Cellular Growth and Proliferation, Cellular Movement, Cell Death and
Survival, Cellular Development. The top canonical pathway in common is Hepatic
Fibrosis / Hepatic Stellate Cell Activation (Table 10).
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Figure 36. Down-regulation of Kenv mRNA expression in MDA-MB-231 xenograft
tumor biopsies. Kenv mRNA expression was significantly decreased in the tumor
biopsies of shRNAenv transduced cells compared with the control cells, as assessed by
qRT-PCR (p = 0.0449).
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Kenv mRNA levels of tumors from shRNA
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Figure 37. Down-regulation of Kenv mRNA expression in MDA-MB-435 eB1
xenograft tumor biopsies. Kenv mRNA expression was significantly decreased in the
tumor biopsies of shRNAenv transduced cells compared with the control cells, as
assessed by qRT-PCR (p = 0.0006).
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Figure 40. GFP+ Panc-2 cells in cultured lung tissue of NSG mice bearing xenograft
tumors. Expression of GFP was observed in three lung biopsies of mice bearing
xenografts of Panc-2 cells transduced with shRNAc (left panel) but not in those with
shRNAenv (right panel).
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Figure 41. GFP+ Panc-2 cells in sections of lung tissue from NSG mice bearing
xenograft tumors. Expression of GFP was observed in sections of lung biopsies from
mice bearing xenografts of Panc-2 cells transduced with shRNA, but not in those with
shRNAenv.
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Figure 42. GFP+ MDA-MB231 cells in cultured lung tissue of NSG mice bearing
xenograft tumors. More GFP+ cells were observed in three lung biopsies of mice bearing
xenografts of MDA-MB-231 cells transduced with shRNAc than in those with
shRNAenv, both in the floating pieces of lung tissues (upper panel) and among the
attached cells (lower panel)
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Figure 43. GFP+ MDA-MB-231 cells in sections of lung tissue from NSG mice bearing
xenograft tumor. More GFP+ cells were observed in sections of lung biopsies from mice
bearing xenografts of MDA-MB-231 cells transduced with shRNAc than those with
shRNAenv.
.
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Table 4. A brief summary of IPA results of shRNA transduced MDA-MB-435 eB1 cells.
Some top Bio-functions and top canonical pathways that are related to Kenv are shown
in the table.
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Table 5. A brief summary of IPA results of SKBR-3 xenografts growing in NSG mice.
Some top Bio-functions and top canonical pathways that are related to Kenv are shown
in the table.
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Table 6. A brief summary of IPA results of SKBR-3 xenografts growing in nude mice.
Some top Bio-functions and top canonical pathways that are related to Kenv are shown
in the table.
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Table 7. A brief summary of IPA results of Panc-2 xenografts growing in nude mice.
Some top Bio-functions and top canonical pathways that are related to Kenv are shown
in the table.
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Table 8. A brief summary of IPA results of Panc-1 xenografts growing in nude mice.
Some top Bio-functions and top canonical pathways that are related to Kenv are shown
in the table.
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Table 9. A brief summary of IPA results of A375 xenografts growing in NSG mice.
Some top Bio-functions and top canonical pathways that are related to Kenv are shown
in the table.
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Cells or xenografts

Panc-1

Panc-2

SKBR-3

SKBR-3

(nude)

(NSG)

eB1

A375

Diseases and Disorders
Cancer

√

√

√

√

√

√

Gastrointestinal Disease

√

√

√

√

√

√

Dermatological Diseases and Conditions

√

√

√

√

Organismal Injury and Abnormalities

√

√

√

√

Molecular and Cellular Functions
Cellular Growth and Proliferation

√

√

√

√

√

√

Cellular Movement

√

√

√

√

√

√

Cell Death and Survival

√

√

√

√

√

Cellular Development

√

√

√

√

√

√

√

Cell Morphology

√

Top Canonical Pathways
Hepatic Fibrosis / Hepatic Stellate Cell

√

√

√

√

√

√

Activation
Axonal Guidance Signaling

√

Table 10. An overall summary of IPA results across all samples. Only Bio-functions or
pathways that are common in more than three samples are listed above.
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Of great interest, we found changes in expression of several genes involved in the
mevalonate pathway, which is very similar to the important findings published by FreedPastor et al. (84), as shown in Figure 44. We then validated our RNA Seq results by
subjecting these genes by qRT-PCR assays (two step). The results showed that all the
genes were downregulated with knockdown of Kenv, and this again matches the results
reported by Freed-Pastor et al. (Figure 45).
4.6 Over-expression of Kenv promoted MCF-10AT cell proliferation and
transformation in vitro
To investigate the roles of Kenv in human cancer in another way, gain-of-fuction
approach was used with over-expression of Kenv in the premalignant human breast cell
line MCF-10AT. The Kenv-expressing lentivector pLVX-Kenv was transduced into
MCF10AT, and the empty vector pLVX was used as control. MCF-10AT cells had an
increased Kenv mRNA expression, and an emerging Kenv protein expression with
transduction of pLVX-Kenv (Figure 46). With over-expression of Kenv, the
proliferation rate of MCF-10AT cells were significantly increased (Figure 47A). In
addition, a soft agar assay showed significantly increased colony formation in pLVXKenv transduced cells compared with the control cells (Figure 47B&C). However, when
subcutaneously inoculated into NSG mice, MCF-10AT cells transduced with pLVXKenv didn’t develop any xenograft tumors after two months post inoculation (data not
shown).
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Figure 45. Validation of genes involved in the mevalonate pathway by qRT-PCR. 8
genes involved in the mevalonate pathway as well as Kenv, were tested by qRT-PCR,
with normalization to RPL32. All genes were down-regulated accompanying by
knockdown of Kenv, and the levels of HMGCR and DHCR24 were significantly
decreased.
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Figure 46. Over-expression of Kenv expression in MCF-10AT by lentivector
transduction. Increased expression of Kenv mRNA was demonstrated in MCF-10AT
cells transduced with pLVX-Kenv compared with pLVX (left panel). The significantly
increased expression of HERV-K env RNA determined by qRT-PCR (p = 0.0002) was
confirmed by RT-PCR (top right panel). Furthermore, the increased expression of Kenv
at the protein level was demonstrated by immunoblot assay using 6H5 mAb (bottom
right panel).
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Figure 47. Promotion of cell proliferation and colony formation of MCF-10AT cells by
pLVX-Kenv. A. MCF-10AT cells transduced with pLVX-Kenv have a significantly
increased proliferation rate than those transduced with pLVX; B. In the anchorageindependent colony formation assay, the colony-formation potential of MCF-10AT was
significantly increased by pLVX-Kenv (p < 0.0001); C. Representative pictures of
colonies formed from MCF-10AT cell transduced with pLVX-Kenv or pLVX.
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Chapter 5 Discussion
In the US, it is estimated that more than 1.6 million new cancer cases will be
diagnosed and more than half a million cancer patients will die in 2013 (54). The high
incidence, high mortality and high cost for treatment of cancer have made it one of the
most serious health issues in the US.
There are many risk factors for cancer development, and among them, viruses are
considered as the second most important one in humans, only exceeded by tobacco
consumption (90). Recently, many publications have been illustrating the association
between HERV-K and cancer. However, as mentioned in Chapter 1, the causal
relationship between the two is still unknown. But some studies (41, 75, 77) have
suggested that HERV-K might play the causal role. Of our great interest, Kenv protein
seems to play an important role in this process, though its actual role remains a mystery.
In this project, we tried to figure out the role(s) of Kenv in carcinogenesis or tumor
progression of human breast cancer, pancreatic cancer and melanoma, whose association
with HERV-K has been intensively investigated in our lab in recent years. We used two
different approaches: knockdown of Kenv in cancer cell lines, to see if down-regulation
of Kenv could make these cancer cell lines become less tumorigenic; over-expression of
Kenv in normal or premalignant cell lines, to see if up-regulation of Kenv could
transform these cell lines.
To study the role of Kenv using the knockdown approach, we first tried short
interfering RNAs (siRNAs). Six individual siRNAs (25-mer) were designed to target
HERV-K env using the Invitrogen Block-iT RNAi Designer and transiently transfected
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into different cancer cell lines to test their knockdown efficacies. Though the knockdown
of Kenv at the mRNA level was observed, reduction of Kenv protein was not observed
with siRNA transfection (data not shown). One reason behind this observation might be
the long half-life of Kenv protein: when we carried out an 35S pulse-chase experiment to
study the half-life of Kenv protein, we did not see an obvious decrease in the level of
35

S-labeled Kenv protein even after 7 days post 35S. The Kenv protein could be so stable

that the siRNAs transiently transfected into the cells might have already been degraded
before the level of Kenv protein went down, though the Kenv mRNA had been knocked
down by these siRNAs. In addition, to investigate the knockdown effect of Kenv in vivo,
stably knocking down of Kenv expression is required, so we decided to use shRNA
approach instead.
Oricchio et al. reported a retroviral vector-based shRNA that could knockdown
HERV-K expression (pS-H-Ki), though it targets HERV-K gag (74). We tried the same
shRNA vector in our lab. With transduction of pS-H-Ki, we did observe the decreased
expression of HERV-K genes and Kenv protein as well as smaller tumor formation in
mice compared to the parent A375 cells. This result is in agreement with Oricchio et al..
However, the transduction of the scrambled control shRNA, or even of the vector control
only (without any shRNA insert), could also lead to the decreased HERV-K expression
and smaller tumor formation in mice compared to the parent cells though there was no
significant difference between the pS-H-Ki transduced cells and the control shRNA
transduced cells. This perhaps resulted from the variance of the single colonies picked up
(following the manufacturer’s manual) or from the long-term drug selection. In addition,
the HERV-K gene we are interested in is env, not gag. So we decided to design our own
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HERV-K-specific shRNA targeting env and to express it in targeting cells using a
lentivector system which has higher transduction efficiency than retroviral vectors .
Kenv-targeting shRNA sequences (19-mer) were designed with the help of the
Invitrogen Block-iT RNAi Designer, and compared to the siRNA sequence (25-mer)
with the best knockdown efficacy among the 6 siRNAs, which was determined by the
previous study. One shRNA sequence that overlaps the majority of the best siRNA
sequence was chosen, and cloned into the pGreenPuro™ lentivector. Because of the high
transduction efficiency of lentivector systems, more than 90% of cells were transduced
as determined by levels of expressed GFP reporter signals. Then the pool of transduced
cells after drug selection, rather than single colonies randomly picked up, were used in
all the assays to minimize the influence of varieties of single colonies.
Our data showed that Kenv expression at both mRNA level and protein level was
successfully knocked down by shRNAenv in all the 6 cell lines we tried (MDA-MB-231,
MDA-MB-435 eB1, SKBR-3, Panc-2, Panc-1 and A375), no matter which cancer types
they belong to (Figures 8-13). Perhaps because of the high variety and complexity of
HERV-K family, shRNAenv didn’t completely, or even nearly, knock out its targeting
gene/protein like other shRNAs reported previously did. However, the in vitro
proliferation and colony formation of all 6 cell lines were significantly decreased
accompanied by knockdown of Kenv (Figures 14-19), and the in vitro migration/
invasion of MDA-MB-231, MDA-MB-435 eB1 and A375 was also decreased (Figures
20-26). In addition, tumor growth in mice in the xenograft models of all the cell lines
were also inhibited by shRNAenv (Figures 27-34) and the in vivo migration of MDAMB-231 and Panc-2 was inhibited by shRNAenv (Figures 40-43). These results strongly
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suggest that Kenv plays a very important role in tumor progression in breast cancer,
pancreatic cancer, and melanoma.
The studies reported by Oricchio et al. (74) and Serafino et al. (75) seemed to
demonstrate the importance of HERV-K Gag protein in melanoma progression as well.
However, when shRNAenv was used to transduce A375 cells, the expression of other
HERV-K genes including gag were decreased; meanwhile, when shRNA targeting
HERV-K gag was used, the expression of other HERV-K genes including env were also
decreased (Figure 48). This could be explained by the RT-PCR results using primers P1
and P3, which is intended to amplify a HERV-K gene fragment that spans the pol and
env regions; the amplicons showed the possible existence of a mRNA with all HERV-K
genes, or HERV-K genomic RNA in A375 cells, and shRNA targeting any single
HERV-K gene may result in knockdown of all the HERV-K genes. So the efficacy of
shRNA targeting HERV-K gag might eventually rely on the knockdown of Kenv, and
combined with our studies in breast cancer with anti-Kenv antibodies (30), we think
Kenv is the very HERV-K protein that influences melanoma progression. However, this
should be further demonstrated by the rescue assay, which we are focusing on right now.
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Figure 48. “Cross-reaction” ability of shRNAs targeting different HERV-K genes.
Multiple shRNAs were used to transduce A375 cells, and all HERV-K genes may be
knocked down by shRNA targeting any HERV-K gene, measured by RT-PCR.
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To understand the mechanism of how Kenv influences the tumorigenic
characteristics of the cancer cell lines, we performed whole genome RNA-Seq analysis
of xenografts from the shRNA transduced SKBR-3, Panc-2, Panc-1 and A375, as well as
of the shRNA transduced MDA-MB-435 eB1 cells, trying to find out the differential
gene expression profiling related to knockdown of Kenv. Then IPA was done to identify
the Kenv-related networks of differentially expressed genes in our samples. In summary,
our results show that Kenv is highly related to cellular growth and proliferation, cellular
movement and cell death and survival, which suggests that to understand how Kenv
works, a close attention need be paid to genes/pathways related to these cellular and
molecular functions.
In particular, we noticed that some genes involved in the mevalonate pathway had a
differential expression in shRNA transduced MDA-MB-435 eB1 cells, and a similar
finding was observed in the important study published by Freed-Pastor et al. (84), as
shown in Figure 44. Thus we performed qRT-PCR following Freed-Pastor et al.,
primarily to validate our RNA Seq results, and the results showed that expression levels
of some genes that are involved in the mevalonate pathway were indeed down-regulated
with knockdown of Kenv (Figure 45). Freed-Pastor’s study demonstrated that the
mevalonate pathway is related to mutant p53 and we also reported that Kenv is related to
p53 pathways (30), so we infer that the Kenv influence cancer development by changing
mevalonate pathways especially in breast cancer, which is intermediated by mutant p53,
given that MDA-MB-435 eB1 is a p53 mutant cell line (though it has different mutations
of p53 than MDA-MB231/ MDA-MB-468 that were used by Freed-Pastor et al.) (91).
However, much further work need to be done to support this notion.
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In addition, the study with over-expression of Kenv approach has just been started.
At the beginning, we expected to find that over-expression of Kenv in the premalignant
human breast cell line MCF-10AT could transform this cell line, like the role of Bmi-1
reported by Datta et al. (92). However, after successfully introducing Kenv into MCF10AT, while we did observe an increased proliferation rate and more colonies formation
in the soft agar assay as expected, we did not find any tumor formation that was resulted
from inoculation of pLVX-Kenv transduced MCF-10AT. This might be because Kenv is
not as oncogenic as Bmi-1, or other co-factors may be also needed to initiate the
malignant transformation. Another possibility is that Kenv could act as a promotor,
rather than initiator, in tumor development. Further studies should be carried out in some
human cancer cell lines (such as human breast cancer cell lines MCF-7 and SKBR-3) to
determine if Kenv over-expression could increase the malignancy of these cancer cell
lines.
This study has a few limitations. First, the studies of melanoma focused on only one
cell line, so the results might not be representative, and thus similar studies should be
carried out with additional melanoma cell lines. Second, the specificity of the shRNAenv
has not been definitively demonstrated, and this should be further addressed by a rescue
assay, which is currently being carried out in our lab. Third, although some possible
pathways through which Kenv might influence human cancer progression have been
proposed by IPA, these pathways have not been validated yet, and the position of Kenv
in these pathways has still not been determined. Additional studies are needed to
illustrate the detail of the pathways. Moreover, the role of Kenv in multiple human
cancers should be further demonstrated with overexpression approaches.
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In summary, our data suggest that Kenv protein could positively influence the
proliferation, migration, invasion, and tumorigenic potential of multiple cancer cell lines,
but it appears that Kenv may not initiate tumor development in vivo. To our knowledge,
this is the first study to illustrate the role of Kenv protein in human breast cancer,
pancreatic cancer, and melanoma. Importantly, here we have briefly described the
pathways in which Kenv protein might be involved in cancer development, paving a way
to study the detailed mechanism of how Kenv protein works in the cells. These results
suggest that Kenv plays specific and important roles in progression of human breast
cancer, pancreatic cancer and melanoma.
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